Drugs / LAT8881
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 missed | ||||||
| Phase 1 | NCT05298306 | May 2022 → May 2023 | radiculopathy | Lateral Pharma Pty Ltd | Completed | Missed primary |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04153409 | Sep 2019 → Feb 2020 | migraine disorder | Lateral Pharma Pty Ltd | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03865953 Comparator | Apr 2019 → Apr 2020 | diabetic polyneuropathy, neuropathy, painful, postherpetic neuralgia | Lateral Pharma Pty Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAT8881 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03865953 ↗ |
| Known as | AOD-9604 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068615 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068615 ↗ |
| Route | Oral | “LAT8881 oral capsule” NCT03865953 ↗ |